Please provide your email address to receive an email when new articles are posted on . Among patients with cardiogenic shock, there was no difference between the inotropic agents milrinone and ...

Contacted by heartwire for comment on their publications, both Cuffe and Young noted that these two papers represent a step forward in the treatment of decompensated heart failure, not just because of ...

Against expectations, critically ill people in cardiogenic shock fared similarly receiving one widely used inotrope or another in the small DOREMI trial. Patients had the same clinical outcomes on ...

New York, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Inotropic Agents Global Market Report 2023" - https://www ...

September 26, 2008 (Toronto, ON)— Would that which is called an inotrope, by any other name, be safer in heart failure? A small dose-ranging study in patients with stable heart failure supports animal ...

Patients with cardiogenic shock were assigned to receive milrinone or dobutamine for inotropic support. There was no significant difference between the two groups in the composite primary outcome of ...

Bedford Laboratories announced the addition of milrinone lactate in 5% dextrose injection (0.2mg/mL) in single-dose PVC flexible containers to its existing milrinone injection line. This product is AP ...

There is little information regarding the comparative hemodynamic effects of adding milrinone or levosimendan to dopamine infusion in hypoxia-reoxygenated (H-R) newborns. Twenty-eight piglets (1–4 d, ...

Inotropic therapy remains a cornerstone in the management of heart failure, targeting the fundamental deficit of impaired myocardial contractility. Traditional positive inotropes act by increasing ...